Jul. 10 at 8:59 PM
$INTS
“Something systemic may be happening — immune activation, antigen release, T-cell response.”
personalised anti-cancer vaccine from the patient’s own tumour”
13 tumours from 10 subjects means it was not just one random lesion in one patient. It happened across multiple patients and multiple lesions. Still small, but much more interesting
The slide also says abscopal effects may be underestimated because small tumours under 1cm weren’t recorded and many tumours above 1cm were untracked due to RECIST target rules.
we only counted what was trackable —the real effect could be broader.
The abscopal slide is the biggest “platform” piece.
Uninjected tumours shrinking is the key. That supports the idea that INT230-6 may not only kill the injected tumour locally, but may trigger systemic immune activity. The company’s March update said about 20% of patients in the >40% group had uninjected tumours shrink, and your slide shows reductions in 13 tumours from 10 subjects.
